Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Marta Novella -Navarro"'
Autor:
Alejandro Balsa, Laura Nuño, Diana Peiteado, Irene Monjo, Alejandro Villalba, Chamaida Plasencia-Rodríguez, Marta Novella -Navarro, JoséLuis Cabrera-Alarcón, Natalia López-Juanes, Elisa Fernández Fernández
Publikováno v:
RMD Open, Vol 9, Iss 3 (2023)
Objectives To analyse the trajectories of Disease Activity Score 28 (DAS28), patient global assessment (PGA) and physician global assessment (PhGA) and to assess their predictive capabilities on difficult-to-treat rheumatoid arthritis (D2TRA) classif
Externí odkaz:
https://doaj.org/article/f1132ea6f20b45d99ec07923a33843a8
Autor:
Chamaida Plasencia-Rodríguez, Ana Martínez-Feito, Marta Novella-Navarro, Rebeca Pérez De Diego, Gema Bonilla, Johanna Elin Gehin, Alejandro Villalba-Yllán, Laura Nuño, Dora Pascual-Salcedo, Pilar Nozal, Mariana Díaz Almirón, Alejandro Balsa
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
BackgroundThe EXXELERATE study revealed poorer clinical outcomes in patients treated with adalimumab (ADL) and baseline rheumatoid factor (RF) above 203 IU/mL. However, responses were similar in patients treated with certolizumab pegol (CZP) regardle
Externí odkaz:
https://doaj.org/article/5c081e86bfe942969ad8d12630838bf4
Autor:
Marta Novella-Navarro, José Luis Cabrera-Alarcón, José Luis Rosales-Alexander, Jorge Juan González-Martín, Ofelia Carrión, Paloma García de la Peña
Publikováno v:
European Journal of Rheumatology, Vol 9, Iss 1, Pp 20-25 (2022)
Externí odkaz:
https://doaj.org/article/19db2754d0d9464d8fc260e7b3b7e7a6
BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
Autor:
Borja Hernández-Breijo, Victoria Navarro-Compán, Chamaida Plasencia-Rodríguez, Ioannis Parodis, Johanna E. Gehin, Ana Martínez-Feito, Marta Novella-Navarro, Araceli Mezcua, David J. Warren, Pilar Nozal, Dora Pascual-Salcedo, Alejandro Balsa
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Immunogenicity related to treatment with TNF inhibitors (TNFi) is one of the causes for the decreased attainment of clinical response in patients with rheumatoid arthritis (RA). The B-cell activating factor (BAFF) may be playing a role in th
Externí odkaz:
https://doaj.org/article/23161f74c66b452fadeaadcaeff92d76
Autor:
Alejandro Balsa, Victoria Navarro-Compán, Laura Nuño, Karen Franco-Gómez, Diana Peiteado, Irene Monjo, Alejandro Villalba, Patricia Bogas, Diego Benavent, Marta Novella-Navarro, Chamaida Plasencia-Rodríguez, Romina Nieto
Publikováno v:
BMJ Open, Vol 12, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/667d1afe2aa7440b8a94b84f3178dba3
Autor:
Marta Novella-Navarro, Chamaida Plasencia, Carolina Tornero, Victoria Navarro-Compán, José L. Cabrera-Alarcón, Diana Peiteado-López, Laura Nuño, Irene Monjo-Henry, Karen Franco-Gómez, Alejandro Villalba, Alejandro Balsa
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-8 (2020)
Abstract Background Biological therapies have improved the clinical course and quality of life of rheumatoid arthritis (RA) patients. Despite the availability and effectiveness of these treatments, some patients experience multiple failures to biolog
Externí odkaz:
https://doaj.org/article/23628a5066f5439fabf843402e0348e9
Autor:
Patricia Bogas, Chamaida Plasencia-Rodriguez, Victoria Navarro-Compán, Carolina Tornero, Marta Novella-Navarro, Laura Nuño, Ana Martínez-Feito, Borja Hernández-Breijo, Alejandro Balsa
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 13 (2021)
Background: Currently, there is contradictory evidence regarding the best strategy to follow after discontinuation of a first biological agent in patients with rheumatoid arthritis (RA). We aimed to compare the long-term efficacy of switching to a se
Externí odkaz:
https://doaj.org/article/37304551fe53486ea600c139c7bab59b
Autor:
Borja Hernández-Breijo, Ioannis Parodis, Marta Novella-Navarro, Ana Martínez-Feito, Victoria Navarro-Compán, Mariana Díaz-Almirón, Dora Pascual-Salcedo, Alejandro Balsa, Chamaida Plasencia-Rodríguez
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 17, p 5207 (2022)
We investigated B-cell-activating factor (BAFF) in relation to response to treatment with TNF inhibitors (TNFis) in rheumatoid arthritis (RA). This was a longitudinal study including 158 patients with RA treated with TNFis and followed up for 6 month
Externí odkaz:
https://doaj.org/article/46be76542a934539a7a8ed55d52844fc
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Currently, there is an increasing interest in treating patients at risk of rheumatoid arthritis (RA) to prevent the development of this chronic disease. In this sense, research has focused attention on the early identification of predictive factors o
Externí odkaz:
https://doaj.org/article/c70d97482bea4beaa260274fe1f43e5f
Autor:
Borja Hernández-Breijo, Claudia M. Brenis, Chamaida Plasencia-Rodríguez, Ana Martínez-Feito, Marta Novella-Navarro, Dora Pascual-Salcedo, Alejandro Balsa
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Tumor necrosis factor inhibitors (TNFi) are widely used for the treatment of patients with rheumatoid arthritis (RA), however a considerable percentage of patients discontinued the therapy. The aim of this study is to explore real-world TNFi survival
Externí odkaz:
https://doaj.org/article/700825b7868849ae99c69339a40b2074